Anavex Life Sciences Corp. | Mutual Funds
Mutual Funds that own Anavex Life Sciences Corp.
Vanguard Total Stock Market Index Fund
1,010,161
2.25%
0
0%
07/31/2018
Vanguard Extended Market Index Fund
566,620
1.27%
0
0%
07/31/2018
Fidelity Spartan Extended Market Index Fund
188,050
0.42%
0
0%
07/31/2018
iShares Micro Cap ETF
104,336
0.23%
0
0.02%
09/06/2018
CREF Stock Account
82,811
0.19%
0
0%
03/31/2018
Fidelity Spartan Small Cap Index Fund
79,774
0.18%
5,777
0%
04/30/2018
Fidelity Spartan Total Market Index Fund
69,965
0.16%
0
0%
07/31/2018
Vanguard Institutional Total Stock Market Index Fund
59,729
0.13%
0
0%
07/31/2018
AXA 2000 Managed Volatility Portfolio
58,495
0.13%
0
0%
03/31/2018
TIAA-CREF Small Cap Blend Index Fund
43,047
0.1%
0
0%
05/31/2018
| Address |
51 West 52nd Street
New York New York 10019
United States
|
|
Employees
|
- |
| Website |
http://www.anavex.com |
| Updated |
07/08/2019 |
| Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY. |
